BioAegis Partners with Prenosis to Develop AI-Driven Precision Medicine for ARDS Treatment
Key Insights
BioAegis Therapeutics (search) has entered a strategic collaboration with Prenosis (search) to apply artificial intelligence and precision medicine approaches to identify patient subgroups most likely to benefit from gelsolin therapy for inflammatory diseases.
The partnership will analyze biospecimens and clinical data from BioAegis' ongoing 600-patient Phase 2 trial evaluating recombinant human plasma gelsolin for moderate-to-severe acute respiratory distress syndrome.
Prenosis (search) recently secured a $20 million BARDA (search) contract to develop AI-enabled companion diagnostics, supporting the collaboration's goal of personalizing treatment decisions based on individual patient biology.
BioAegis Therapeutics (search) has announced a strategic collaboration with Prenosis (search) to advance artificial intelligence-driven precision medicine for inflammatory diseases, focusing on the company's novel recombinant human plasma gelsolin therapy. The partnership aims to identify biological signatures and patient subpopulations most likely to benefit from this innovative immune modulator.
AI-Powered Analysis of Phase 2 ARDS Trial
Under the collaboration agreement, Prenosis (search) will apply its precision medicine platform to analyze biospecimens and clinical data from BioAegis' ongoing 600-patient Phase 2 clinical trial, BTI-203. This global study is evaluating recombinant human plasma gelsolin (rhu-pGSN) for the treatment of moderate-to-severe acute respiratory distress syndrome (ARDS), a life-threatening condition characterized by severe lung inflammation and respiratory failure.
The BTI-203 trial is enrolling patients across sites in the United States, Canada, and Europe, with support from federal funds through the U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, and the Biomedical Advanced Research and Development Authority (BARDA (search)) under contract number 75A50123C00067.
"Solving the most challenging inflammatory diseases is achievable with the integrated power of host-directed therapeutics and precision analytics," commented Susan Levinson, Ph.D., CEO of BioAegis. "In collaboration with Prenosis (search), we expect to transform how inflammatory disease is treated."
Precision Medicine Platform Integration
Prenosis (search)' platform integrates multi-dimensional biological data with machine learning to identify clinically meaningful patterns in complex diseases. This approach builds on the company's broader mission to combine diagnostics and therapeutics for more personalized treatment strategies in critical care conditions such as sepsis and ARDS.
The collaboration gains additional significance from Prenosis (search)' recent momentum, including a $20 million contract from BARDA (search) to support development of its precision medicine platform and AI-enabled companion diagnostics. These efforts focus on identifying patients most likely to benefit from specific therapies, directly aligning with the collaboration's objectives.
"We are incredibly grateful for the opportunity to partner with the team at BioAegis on this initiative," stated Bobby Reddy, Jr., Ph.D., CEO and co-founder of Prenosis (search). "This collaboration is one more step towards our vision, and we are excited to work with BioAegis toward a future where treatment decisions are guided by each patient's unique biological profile."
Novel Mechanism of Gelsolin Therapy
BioAegis' portfolio centers around plasma gelsolin, a highly conserved and critical immune regulatory protein that rebalances dysfunctional inflammation without suppressing immune function. Gelsolin is naturally occurring in humans and plays a critical role in regulating the body's inflammatory response and supporting innate immune function.
In patients with severe inflammation, plasma gelsolin levels become depleted, and replenishment with rhu-pGSN has the potential to restore immune balance, enhance pathogen clearance, and reduce tissue damage. In critical illness, gelsolin levels collapse, causing adverse outcomes, making supplementation a direct approach to addressing this deficit.
Research has demonstrated that gelsolin therapy can modulate the activation of the NLRP3 inflammasome, enhance uptake and killing of microbial pathogens by innate immune cells, bind to and remove harmful inflammatory mediators and toxic actin released from damaged cells, and regulate macrophage phenotype to modulate inflammation.
Unlike conventional anti-inflammatory therapies, recombinant gelsolin restores immune balance without suppressing the body's ability to fight infection, representing a transformative approach to treating inflammatory diseases.
Intellectual Property and Development Pipeline
BioAegis holds exclusive licensing rights to broad, worldwide intellectual property through Harvard-Brigham and Women's Hospital (search), with over 40 patents issued covering inflammatory disease, infection, renal failure, neurologic disease, and frailty. The company will also have U.S. biologics exclusivity and has recently filed new intellectual property in areas of unmet medical need.
This collaboration represents an important step toward integrating therapeutic innovation with advanced diagnostic insights, with the goal of improving outcomes in ARDS and other inflammation-driven diseases through precision medicine approaches.